Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune ...
Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback